Ixekizumab联合Tirzepatide在超重或肥胖的银屑病关节炎成人中比单用Ixekizumab获得更好的疾病控制:随机临床试验结果
TOGETHER-PsA是一项3b期随机52周试验,纳入271例活动性银屑病关节炎(PsA)且超重(BMI≥27至<30并至少一种体重相关合并症)或肥胖(BMI≥30)的成人,比较Ixekizumab(IXE)联合Tirzepatide(TZP)与单用IXE。主要终点为36周时同时达到ACR50和体重下降≥10%,联合组为31.7%,单用组为0.8%(P<0.001);联合组ACR50也更高(33.5% vs 20.4%,P=0.02),安全性特征与既往研究一致。
要点
- IXE联合TZP在36周同时达到ACR50和体重下降≥10%的比例显著高于单用IXE(31.7% vs 0.8%,P<0.001)。
- 联合组ACR50应答率显著高于单用组(33.5% vs 20.4%,P=0.02),第4周即出现显著早期分离(名义P<0.05)。
- 联合组在ACR20、最小疾病活动度、PASI绝对评分及患者报告结局方面均优于单用组,安全性特征与既往研究一致。
核心结论
- 在活动性PsA且超重或肥胖的成人中,IXE联合TZP较单用IXE在PsA疾病活动度、躯体功能、体重下降和生活质量方面取得有临床意义的改善,且无新的安全性问题。
研究设计与样本
- TOGETHER-PsA(NCT06588296)为3b期随机52周试验,纳入271例活动性PsA且超重(BMI≥27至<30并至少一种体重相关合并症)或肥胖(BMI≥30)的成人,随机分为IXE+TZP组(n=138)和IXE组(n=133),使用美国获批剂量。
主要发现
- 36周主要终点(同时达到ACR50和体重下降≥10%)在IXE+TZP组为31.7%,单用IXE组为0.8%(P<0.001)。
- ACR50在IXE+TZP组为33.5%,单用IXE组为20.4%(P=0.02),第4周出现显著早期分离(名义P<0.05)。
- IXE+TZP在ACR20(名义P<0.001)、最小疾病活动度(名义P<0.05)和PASI绝对评分(名义P<0.01)方面较单用IXE有名义显著改善。
- 患者报告结局方面,IXE+TZP较单用IXE显著改善HAQ-DI(∆ -0.2;名义P<0.001)和FACIT-Fatigue(改善3.8;名义P<0.01)。
- 安全性评估包括不良事件、治疗中出现的不良事件和严重不良事件,安全性特征与每种药物既往研究一致。
关键数值与推荐
- 主要终点为36周时同时达到ACR50和体重下降≥10%。
- 超重定义为BMI≥27至<30并至少一种体重相关合并症,肥胖定义为BMI≥30。
- ACR50在IXE+TZP组为33.5%,单用IXE组为20.4%(P=0.02)。
- 主要终点达标率在IXE+TZP组为31.7%,单用IXE组为0.8%(P<0.001)。
临床怎么用
- 对于活动性PsA合并超重或肥胖的成人,可考虑IXE联合TZP以同时改善关节疾病活动和体重。
- 联合治疗在ACR50、ACR20、最小疾病活动度、PASI及患者报告结局方面均优于单用IXE,且安全性特征与既往研究一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight-related comorbidity or obesity. METHODS: TOGETHER-PsA (ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52-week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30) using US-approved doses for IXE and TZP. The primary end point was simultaneous achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) and ≥10% weight reduction at 36 weeks. Key secondary outcomes included ACR50. Additional secondary outcomes and patient-reported outcomes (PROs) were assessed. Safety was assessed as adverse events (AEs), treatment-emergent AEs, and serious AEs. RESULTS: A total of 271 participants were randomized (IXE + TZP, n = 138; IXE, n = 133). The primary end point was achieved with significant improvements in the IXE + TZP arm (31.7%) compared to IXE alone (0.8%) (P < 0.001). Greater improvements in ACR50 were demonstrated in IXE + TZP (33.5%) versus IXE alone (20.4%) (P = 0.02), with significant early separation at week 4 (nominal P < 0.05). IXE + TZP demonstrated nominally significant improvements in ACR20 (P < 0.001), minimal disease activity (P < 0.05), and absolute Psoriasis Area and Severity Index score (P < 0.01) compared to IXE alone. IXE + TZP demonstrated significant improvements in PROs, including Health Assessment Questionnaire-Disability Index (∆ -0.2; nominal P < 0.001) and Functional Assessment of Chronic Illness Therapy-Fatigue (improvement of 3.8; nominal P < 0.01) compared to IXE alone. Safety profiles were consistent with previous studies for each drug. CONCLUSION: Participants with active PsA and complex inflammatory-metabolic disease achieved clinically meaningful improvement of PsA, physical function, weight reduction, and quality of life when treated with IXE + TZP compared to IXE alone, with no new safety concerns.
引用
- Merola JF, Mease P, Kivitz A, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026. PMID: 41903163. doi:10.1002/art.70134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。